Tau-Targeting Therapies for Neurodegenerative Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Aging".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 235
Special Issue Editors
2. Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain
3. Institute of Neurosciences, University of Barcelona, 08028 Barcelona, Spain
Interests: neurodegenerative diseases; cellular prion protein; tau; synuclein; axon regeneration; lab on chip devices for neurodegeneration
Interests: neurodegenerative diseases; Alzheimer’s disease; tau; microtubules, phase separation; solid transition; tau fibers; neurons; axonal transport
Special Issue Information
Dear Colleagues,
The aim of this Special Issue is to review the latest advancements in strategies to treat tau pathology in Alzheimer’s disease (AD) and other neurodegenerative diseases. AD affects around 50 million people worldwide and, as society ages, it is becoming a significant economic and social problem. Despite tremendous efforts to find a treatment for this devastating disease, little success has been achieved. A shift in the therapeutic strategy is therefore necessary. Neurofibrillary tangles enriched in hyperphosphorylated tau are, together with amyloid beta (Aβ) plaques, the two pathophysiological hallmarks of AD. Although tau mutations are not genetically linked to AD, tau fibers correlate better with cognitive decline and the disease progression. In addition, tau reduction ameliorates Aβ toxicity and cognitive impairment in different AD models. These, among other evidence, suggest a central role for tau in neuronal degeneration in AD. Thus, tau-targeting therapies are now in focus as an alternative or complementary strategy to that targeting Aβ pathology or microglia activation in AD.
In this Special Issue, we would like to provide an up-to-date collection and future perspective on: (i) active and passive tau immunotherapy; (ii) antisense oligonucleotides (ASOs) or other RNA-based strategies to reduce tau protein; (iii) strategies to inhibit tau phosphorylation; (iv) compounds targeting tau aggregation; and (v) approaches to enhance tau degradation. For this Special Issue, we welcome original research articles and review articles. We want to review results from compounds that are already in a clinical trial phase, as well those successfully reducing tau pathology, in cellular or mouse models. We also welcome perspectives on new technology or strategies.
Prof. Dr. José Antonio Del Río Fernández
Dr. Amayra Hernández Vega
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- antibodies
- vaccines
- ASOs
- tau PTMs
- phosphorylation
- acetylation
- aggregation
- degradation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
